

## Special Issue

# Antimicrobial Stewardship in Solid Organ Transplantation: Optimizing Management of Infections Caused by Resistant Organisms

### Message from the Guest Editor

This Special Issue focuses on the critical topic of antimicrobial stewardship in the context of solid organ transplantation.

The Special Issue begins by highlighting the unique vulnerabilities of solid organ transplant patients to infectious complications, related to their underlying medical conditions, their immunosuppressed state and the use of antimicrobials during various stages of the transplantation process.

Additionally, the Special Issue delves into the emerging therapeutic options for resistant infections in solid organ transplant patients. It discusses the use of novel antimicrobial agents, combination therapies and adjunctive interventions, such as immunomodulatory approaches, to combat multidrug-resistant infections.

Overall, this Special Issue serves as a valuable resource for transplant clinicians, infectious disease specialists and healthcare policymakers, providing a deeper understanding of the challenges and emerging solutions in the management of antimicrobial resistance in solid organ transplant recipients.

---

### Guest Editor

Dr. Abhay Dhand

Westchester Medical Center/New York Medical College, Departments of Medicine & Surgery, Valhalla, NY, USA

---

### Deadline for manuscript submissions

31 August 2025



## Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/214851](https://mdpi.com/si/214851)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).